Trial site
Huai'an First People's Hospital
Huai'an, Jiangsu 223300, ChinaNot linked to an institution yet
- 17running trials
- 12closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 24 trials
- Phase 2/32 trials
- Phase 42 trials
- Status
- Completed12 trials
- Recruiting10 trials
- Active, not recruiting5 trials
- Not yet recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche3 trials
- Pfizer2 trials
- Shenzhen HighTide Biopharmaceutical Ltd.2 trials
- Antengene Biologics Limited1 trial
- Atom Therapeutics Co., Ltd1 trial
- and 20 more
Running trials
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Yong Gao
Recruiting
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
NCT07063797· Peking Union Medical College Hospital· Source
Contact: Li Mao, MD
Recruiting
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
NCT07095790· Phase 4· Second Affiliated Hospital of Soochow University· Source
Contact: Kun An
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
NCT05230914· Xinqiao Hospital of Chongqing· Source
Contact: Mingchao Li, MS
Active, not recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source
Recruiting
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
NCT06708156· Phase 3· Oupushifang Pharmaceutical Technology Co., Ltd.· Source
Contact: Chaopeng Li
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Chunling Wang
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· Phase 3· Eli Lilly and Company· Source
Contact: Xin Jin (principal investigator)
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Jianqiang Zhao, M.D.
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513· Southeast University, China· Source
Contact: Xiangcheng Zhang
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Xiwen Zhang, MD
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166· Phase 2· Wenjun Cheng· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
NCT07807007· Phase 2· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source
Completed
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229· Phase 2· Atom Therapeutics Co., Ltd· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
NCT06350890· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source
Completed
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
NCT06103825· Phase 3· Ignis Therapeutics (Suzhou) Limited· Source
Completed
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
NCT06429384· Phase 2· Beijing Tiantan Hospital· Source
Completed
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source
Completed
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT05555706· Phase 2/3· Shanghai Jiaolian Drug Research and Development Co., Ltd· Source
Completed
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
NCT05352516· Phase 3· Shanghai Henlius Biotech· Source
Completed
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
NCT06500689· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source
Completed
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT04540211· Phase 3· Hoffmann-La Roche· Source
Report an error